Apple Watch receives FDA approval for its groundbreaking hypertension detection feature. Rollout begins next week, marking a major step in digital health technology.



In a landmark decision, the U.S. Food and Drug Administration (FDA) has officially approved Apple Watch’s new hypertension detection feature, making it the first wearable device to gain regulatory clearance for monitoring high blood pressure. The update is set to roll out globally starting next week, further cementing Apple’s role in the digital health industry.


According to Apple, the new feature uses advanced sensors and machine learning algorithms to detect early signs of hypertension without requiring a traditional cuff. By continuously monitoring changes in blood flow and cardiovascular activity, the Apple Watch can alert users to potential risks, empowering them to seek medical advice before conditions worsen.


Health experts are calling this approval a “game-changer” for millions of people worldwide who suffer from undiagnosed or uncontrolled hypertension. The World Health Organization (WHO) estimates that more than 1.2 billion people globally live with high blood pressure, a leading cause of stroke and heart disease.


Apple stated that the feature will be part of the upcoming watchOS update. Users will receive notifications if irregular patterns are detected, along with detailed reports that can be shared directly with healthcare providers. The company emphasized that while the Apple Watch is not a replacement for professional medical equipment, it can play a critical role in early detection and prevention.


The rollout will begin in the United States next week, with plans to expand availability to other countries over the coming months, subject to regulatory approvals.


With this milestone, Apple has positioned the Apple Watch not just as a fitness tracker but as a powerful medical device, potentially revolutionizing how people monitor and manage chronic health conditions.